

STELLAR³¹¹

Print or download these questions to ask your doctor and bring them with you to your next appointment.

Learn More About a Clinical Research Study for Neuroendocrine Tumors

This guide can help you talk with your doctor about joining a clinical research study. The first step is to ask your doctor if you may be eligible to take part in this study and decide if this is the right option for you.

STELLAR-311 is a clinical research study to check how a new investigational drug, zanzalintinib, works compared to an approved drug, everolimus, as a potential treatment for neuroendocrine tumors that are advanced or have spread to other parts of the body (metastatic). More information about STELLAR-311 can be found at stellarnetstudy.com or on clinicaltrials.gov by searching for **NCT06943755**. Ask your doctor if you may be eligible.

Questions to Help You Start the Conversation About:

Study Participation

- ☐ What are my treatment options? Is a clinical research study an option for me?
- ☐ What are the potential risks and benefits?
- ☐ What if I decide to leave the study early?
- ☐ Will I be able to get other treatment if the medicines in the study don't work for me?
- ☐ How will my safety be monitored during the study?
- ☐ Are translation services offered? Can you share materials in my native language?

Impact on Daily Life

- ☐ Is there a clinical study site near me?
- ☐ How long will I be in the study?
- ☐ How often will I have to visit the study site?
- ☐ Will I have to stay overnight in a hospital?
- ☐ Can I bring a support person/family member to my study visits?
- ☐ Will the study keep me or my family from our normal daily life?

Financial Costs

- ☐ Will it cost me anything to be in the study?
- ☐ Will the medications be covered by my health insurance?
- ☐ Will I be able to continue working if I participate in the study?

If your doctor is not taking part in STELLAR-311 research, you may want to discuss these questions with a doctor who is.

For more information, please call Exelixis Medical Information at **1-888-393-5494** (toll-free) or **1-303-389-1847**, or email medinfo@exelixis.com.

EXELIXIS IS DEDICATED TO ENSURING THE INCLUSION OF INDIVIDUALS FROM DIVERSE BACKGROUNDS IN OUR CLINICAL TRIALS. ZANZALINTINIB HAS NOT BEEN APPROVED BY REGULATORY AUTHORITIES. THE SAFETY AND EFFECTIVENESS OF ZANZALINTINIB HAVE NOT BEEN ESTABLISHED AND ARE BEING STUDIED AS PART OF THIS CLINICAL TRIAL.